aesgp programme

Citizen empowerment:

A megatrend of the 21st century51st AESGP Annual Meeting

Conference programme and list of participants

Barcelona26-28 May 2015Hilton Diagonal Mar

AESGP Programme_56pp_V3.indd 1 20/05/2015 16:32

AESGP CONFERENCE ON YOUR MOBILE Download aesgp2015

Speakers bios

What isdiscussed and when

Ask questions to speakers

Who is at the conference

Available presentations are uploaded at aesgp.eu/p51


Table of content

Programme overview 4

Conference area 6

Opening event 9

Sessions | Speakers and background information 12

Closing event 39

Next AESGP Conferences 41

Medicines and Medical Devices Data Bank 42

Food Supplements Data Bank 44

List of participants 46

Get your badge from the AESGP Welcome Desk:

Open (see floorplan p6)

Simultaneous translation

The conference languages are English and Spanish. Simultaneous translation in French will be provided.

Hilton WiFi

Username: AESGP

Password: aesgp2015

Conference 3


ProgrammeProgramme

09:00-10:30 11:00-12:30 Wednesday

27 May 2015

09:00-10:30 11:00-12:30 Thursday 28 May 2015

4 Conference

Self-care medical devices and food supplements: New drivers for the self-care market? Hubertus Cranz, AESGP Director General Valeriu Curtui, Head of the Nutrition Unit, European Food Safety Authority (EFSA) Gwenole Cozigou, Director, DG GROW, European Commission Werner Knoess, Chair, Herbal Medicinal Products Committee (HMPC), European Medicines Agency (EMA)

Switching: A mega trend? Suneet Varma, President, Consumer Healthcare, Pfizer Erin Gainer, Chief Executive Officer, HRA Pharma Darragh O’Loughlin, President, Pharmaceutical Group of the European Union (PGEU) Belén Crespo, Agency for Medicinal Products and Medical Devices, Spain

Consumer Health Industry: how to provide the best service? Pedro Nueno Professor in the Department of Entrepreneurship, IESE Business School and Professor and President, CEIBS (Shanghai, Beijing)

Global perspectives on Citizen Empowerment: What I would change if I could Roger Scarlett-Smith AESGP President Andy Tisman IMS Health Dagmar Roth-Behrendt Former Member of the European Parliament

New technology - new guidance - better self-care Brian McNamara, Head of Americas and Europe, GSK Consumer Healthcare Ryan Olohan, Industry Director, Healthcare, Google Inc Sastry Chilukuri, Principal, McKinsey&Company Didier Deltort, Global Monitoring Solutions General Manager, General Electrics Healthcare, Finland Carlos Lens, Ministry of Health, Spain

12:30-14:00 Lunch 10:30-11:00 Break


16:15-17:15

ProgrammeProgramme

How to ensure availability of safe products? Vincent Warnery, Senior Vice President, Global Consumer Healthcare Division, Sanofi Natalie Gauld, Director, Pharmacy Projects and Alison van Wyk, Professional Services Manager, Green Cross Health, New Zealand Sarah Branch Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom Belén Escribano, Agency for Medicinal Products and Medical Devices, Spain Stefano Soro, European Commission

15:30-16:00 Break

16:00-17:30

Conference 5

HRA

n

Perspectives for the future Roger Scarlett-Smith AESGP President Peter Liese, Member of the European Parliament Noel Wathion, European Medicines Agency (EMA) Invitation to the 52nd AESGP Annual Meeting 31 May – 2 June 2016 in the Divani Apollon Hotel, Vouliagmeni, Athens, Greece George Dokios, Executive Director, Association of the Greek Self-Care, Industry, EFEX

19:00 Closing dinner

How to make health care af-fordable? Jaume Pey, Director General, anefp, Spain Peter Schneider, Researcher, Austrian Health Institute Laura Pellisé, Senior Researcher Center for Research in Health and Economics (CRES) at the University Pompeu Fabra (UPF), Barcelona Toni Gilabert, Director of Pharmacy Management and Pharmacoeconomics, Catalonia Health Department Nikos Maniadakis, Associate Dean, National School of Public Health, Greece

15:30-16:00 Break

The new European Union platform for the promotion of self-care systems Rosa Suñol, Director General, Avedis Donabedian Institute, Barcelona Birgit Beger, Secretary General of the Standing Committee of European Doctors (CPME) Cristina Cabrita Senior Project Officer, Portuguese Consumer Organisation (DECO) on behalf of the European Consumer Organisation (BEUC) Carmen Peña President, International Pharmacists Federation (FIP)

17:30 End of 1st day

-

re

n

14:00-15:30

14:00-15:45


Hilton Diagonal Mar Conference area

Ground floor

Conference hall

Hotel reception

Entrance to the hotel

Foye

r / C

offe

e st

atio

n

AESGP Welcome Desk

Lift to rooms

Entrance to the conference area

WiFi

Username: AESGP

Password: aesgp2015

6 Conference


Hilton Diagonal Mar

Floor 1

Lift to rooms

Hotel restaurant

* In case of bad weather, lunch on 27 and 28 May 2015 will be served in the hotel restaurant on the 1st floor

Conference 7


Hilton Diagonal Mar Conference area

Floor 2

Pergola / Terrace*

* If weather permits, lunch on 27 and 28 May 2015 will be served on the terrace located on the 2nd floor

8 Conference


Tuesday 26 May 2015

18:30

Departure of buses from the Hotel Hilton Diagonal Mar

19:00

Reception in the neoclassical courtyard of the Casa Llotja de Mar

20:00

Welcome by Roger Scarlett-Smith, AESGP President

Jordi Ramentol, President anefp, CEO Ferrer

Cristina Iniesta, Health Delegate of City Council & President, Public Health Agency, Barcelona

Agustin Rivero, Director General, Ministry of Health, Spain

Boi Ruiz, Minister of Health, Catalonia

followed by dinner

Opening event

22:30

Return by buses

Dress code: Business

Conference 9


Casa Llotja de Mar

Roger Scarlett-Smith President AESGP, GSK Consumer Healthcare Roger Scarlett-Smith graduated with a Master in Law from St. John’s College, Cambridge University. He started his career as a graduate recruit in marketing at Procter and Gamble. He joined GlaxoSmithKline Consumer Healthcare in 1984. His roles included running the Consumer Healthcare businesses in the UK, Australia and New Zealand as well as North America, and Europe. He also served as President of the Proprie-tary Association of Great Britain (PAGB). He has been serving as Presi-dent of AESGP since July 2014.

The Casa Llotja de Mar will provide an outstanding setting for the start of the event. It is located on the sea front in the historical center of Barcelona and is one of the most significant and splendid monuments representing the economy and culture of the city.

It was built in the second-half of the 14th century, the most brilliant period of Catalan Gothic and served as the city’s medieval stock exchange (more affectionately known as La Llotja). The centrepiece of the premise is the fine Gothic Saló de Contractacions (Contracts Hall), where the opening dinner of the 51st AESGP Annual Meeting will take place.

These and five other halls were encased in a neoclassical shell in the 18th century. The stock exchange was in action until well into the 20th century and the building remains in the hands of the city’s chamber of commerce.

10 Conference


Biographies

Conference 11

Jordi Ramentol President anefp, CEO Ferrer Jordi Ramentol has a Degree in Chemistry and a Global Executive MBA from IESE and the Internationales Führungsprogram.experience in the pharmaceutical and chemical industries, including 25 years in BASF Group. Before joining Ferrer in 1999, he worked as Mana-ging Director of Laboratorios Lacer. In Ferrer, he held the position of Managing Director before becoming CEO in 2004. From 2010 to 2012, he was the President of Farmaindustria, and he is, at present, the President of ANEFP, the Spanish Consumer Healthcare Association, a position which he has hold since October 2012.

Agustin Rivero Director General, Ministry of Health, Spain

Cristina Iniesta Health Delegate of City Council & President, Public Health Agency, Barcelona

Boi Ruiz Minister of Health, Catalonia Boi Ruiz qualified as a doctor at the University of Barcelona, and recei-ved a diploma in hospital management from Barcelona's EADA Business School. He trained in orthopedic surgery and traumatology at Barcelo-na's Hospital Clinic and practiced at a number of public hospitals in Catalonia. Later, he held a range of managerial positions in Catalonia's National Health Service. As a health and healthcare expert, he has been a member of the Spanish Congressional Subcommittee on Health and Consumer Affairs for the Consolidation and Modernization of the Na-tional Health and has appeared as an expert witness on a number of occasions before healthcare committees in the Catalan Parliament, the Spanish Congress, and the Spanish Senate. . Mr Ruiz was appointed Minister of Health of Catalonia in 2010.


Consumer Health Industry: How to provide the best service?

Wednesday 27 May 2015 09:00-10:30

An overall perspective for the consumer health industry will be provided by

a distinguished expert of a leading management school.

– Pedro Nueno, Professor in the Department of Entrepreneurship, IESE

Business School and Professor and President, CEIBS (Shanghai, Beijing)

Session 1

10:30 - 11:00 Break

Global perspectives on Citizen Empowerment: What I would change if I could

Representatives from market research, industry and politics will discuss

where we stand with self-care and citizen empowerment and what needs to

be done to make progress in the future.

– Roger Scarlett-Smith, AESGP President

– Andy Tisman, IMS Health

– Dagmar Roth-Behrendt, Former Member of the European Parliament

12 Conference


Pedro Nueno Professor in the Department of Entrepreneurship, IESE and Professor and Presi-dent, CEIBS (Shanghai, Beijing) Pedro Nueno’s areas of specialization include entrepreneurship and starting new ventures; management of technology and innovation: management of privatization and turnaround processes; industrial alliances; joint-ventures and acquisitions; industrial procurement, and supply-chain management. Mr Nueno holds the Bertran Foundation Chair of Entrepreneurship at IESE and the Chengwei Ventures Chair on Entrepreneurship at CEIBS.

Andy Tisman Senior Principal, Consumer Health, IMS Health. Before joining IMS, Andy Tisman was Managing Consultant at a healthcare strategy and marketing consultancy boutique based in the UK. He worked around the world for major clients such as Bayer, Novartis, Pfizer, Sanofi- Aventis and GlaxoSmithKline, and has extensive experience of brand/ cate-gory strategy development. He also has extensive Pharma and OTC/ Con-sumer Health marketing management experience from over 15 years with SmithKline Beecham in local and international (pan-European and global) roles. He joined IMS in 2005 as Senior Principal to lead the development of the Consumer Health consulting business.

Dagmar Roth-Behrendt Former Member of the European Parliament Dagmar Roth-Behrendt studied law at the University of Marburg, Germany. Between 1979 and 1989, she worked as a lawyer, and was later employed as legal advisor in the chancellery of the Governing Mayor of Berlin. Be-tween 1989 and 2014, Mrs Roth-Behrendt was a Member of the European Parliament and had several key responsibilities, including: Spokeswoman of her political group in the Committee on the Environment, Public Health and Consumer and Vice-President of the European Parliament. She was also a representative of the European Parliament at the High Level Pharma-ceutical Forum and the contact person for the European Parliament at the European Medicines Agency. In March 2015, Mrs Roth-Behrendt was ap-pointed Special Advisor to the EU Health Commissioner Vytenis Andriukai-tis.

Biographies

Conference 13


New technology - new guidance - better self-care

This session will discuss the implications of new technologies and new media

on health information and citizens behaviour.

– Brian McNamara, Head of Americas and Europe, GSK Consumer Healthcare

– Ryan Olohan, Industry Director, Healthcare, Google Inc

– Sastry Chilukuri, Principal, McKinsey&Company

– Didier Deltort, Global Monitoring Solutions General Manager, General Electrics Healthcare, Finland

– Carlos Lens, Ministry of Health, Spain

Session 2

11:00-12:30

Wednesday 27 May 2015

12:30 - 14:00 Lunch

14 Conference


Biographies

Brian McNamara Head of Americas and Europe, GlaxoSmithKline Consumer Healthcare Brian McNamara has a Master of Business Administration in finance and a bachelor’s degree in electrical engineering. He began his career at Procter & Gamble Co., Cincinnati, and joined Novartis in 2004 as Senior Vice President and General Manager of Novartis OTC North America. He served as President of Novartis OTC Europe from 2007 until 2010, and was then appointed global President of Novartis OTC until the establishment of the joint ven-ture with GlaxoSmithKline Consumer Healthcare in February 2015.

Ryan Olohan Industry Director, Healthcare, Google Inc Ryan Olohan holds a bachelors in business management from Provi-dence College. As the Industry Director for Healthcare at Google, Ryan Olohan leads the teams responsible for developing and managing Google's relationships with pharmaceutical and consumer health com-panies. Before Healthcare, Ryan spent the majority of his over six years at Google as the Head of Consumer Packaged Goods. Outside of his day job, Ryan is a frequent speaker at industry events and is on the Advisory Board for the New Jersey Institute of Technology. Prior to joining Google, Ryan was a VP at The Bank of New York Mellon, the Director of Sales at Next Jump Inc., and got his digital education at the search marketing agency, Reprise Media.

Conference 15

Sastry Chilukuri Principal, McKinsey&Company Sastry Chilukuri has a B. Tech from the Indian Institute of Technology and an MBA from Kellogg School of Management, Northwestern Univer-sity. Prior to joining McKinsey, he was employed by GE Healthcare for over 6 years. He held multiple roles in product development and operations, managing global development teams. Mr Chilukuri is now a Principal in McKinsey and Company’s New Jersey Business Technology Office, where he focuses on strategy, technology and operations for the pharmaceuti-cal and medical device sector.


Biographies

Didier Deltort Global Monitoring Solutions General Manager, General Electrics Healthcare, Finland Didier Deltort has a degree in Biomedical Engineering from UTC Compiegne. He spent his entire career in healthcare medical devices, diagnostic imaging and IT. His latest position at GE Healthcare included: European GM Life Care Solutions, EMEA Computed Tomography GM, Middle-East, Africa, Turkey and Central Asia GM. His current position is Global General Manager of GE Healthcare Monitoring Solutions. He is also leading the General Electrics Healthcare operations in Finland.

Carlos Lens Ministry of Health, Spain Carlos Lens holds a degree in Pharmacy and in Economy/Business Administration, as well as a PhD in Pharmacology. Previously , Mr Lens had several top management position in pharmaceutical companies. Since 1996, he has had different positions such as Secretary-General and Director of the Spanish Agency for Medicines and Healthcare Products, Board Member of the European Medicines Agency (EMA), and Director of the Centre for the Coordination of Ethics Research Committees. In 2012, he took over the responsibility as Deputy Director General of Medicines and Healthcare Products at the Spanish Ministry of Health.

16 Conference


How to make health care affordable?

Numerous studies carried out over the last years show the economic and social value of self-care. This session will present the results of new work done on a pan-European level as well as in Spain and Greece. Participants will get insight in new methodologies applied which should be helpful for all kind of similar work in the future.

– Jaume Pey, Director General, anefp, Spain

– Peter Schneider, Researcher, Austrian Health Institute

– Laura Pellisé, Senior Researcher Center for Research in Health and

Economics (CRES) at the University Pompeu Fabra (UPF), Barcelona

– Toni Gilabert, Director of Pharmacy Management and

Pharmacoeconomics, Catalonia Health Department

– Nikos Maniadakis, Associate Dean, National School of Public Health, Greece

Session 3

14:00-15:30


15:30-16:00 Break

Conference 17


Biographies

Jaume Pey Executive Director, anefp, Spain He holds a Degree in Business Administration and a Master Degree from the University of ESADE. He began his professional career in the pharma-ceutical sector at Sanofi, moving on to Bayer, where he worked as Phar-macy Sales and Marketing Director. In November 1997, he joined the agency Olgilvy One as deputy general director, and a year and a half later he became director of OTC Division of Novartis, a job that he held for five years until he joined Zambon as general director for the Iberian Pen-insula, where he remained until September 2012. Since November 2012 he manages the Spanish Association for the self-care products (anefp).

Peter Schneider studied Economics at the University of Vienna, Austria. After his graduation in 2010 he got a scholarship for the Erasmus Mun-dus Master Programme “Economics of International Trade and European Integration” (EITEI), hosted by the Staffordshire University, UK, the Uni-versity of Antwerp, BE and the University of Economics in Prague, CZ. In his master thesis, he examined the effects of political and economic inte-gration on self-assessed well-being in Central European countries. Since 2011, Peter has been doing his PhD at the University of Graz, Austria. He joined the Health Economics Department at the Austrian Health institute in 2014 and has worked on access to high-cost and specialised medi-cines, pricing and reimbursement of medicines, and comparison between health systems.

Peter Schneider Researcher, Austrian Health Institute

Laura Pellisé Director and Senior Research Fellow of the Centre for Research in Health and Economics (CRES).

Graduated in Economics at the University of Barcelona, Laura Pellisé holds a MSc in Health Policy and Management from Harvard Universi-ty and a Ph.D. in Economics from Pompeu Fabra University. She joined CRES-UPF in 2011, bringing together a sound knowledge of the Spanish health care and biomedical arenas, and her management, teaching and research skills. Between 2011 and 2013, she was CRES Director. She is the co-director of the Master in Health Service Administration and Man-agement, jointly organised by the Continuing Education Institute of the UPF and the Gaspar Casal Foundation of Madrid, and of the "Postgraduate Diploma in Clinical Management", organised by the same foundation in collaboration with the Barcelona School of Management (BSM-UPF).

18 Conference


Biographies

Antoni Gilabert Director of Pharmacy Management and Pharmacoeconomics, Cata-lonia Health Department Antoni Gilabert holds a PhD in Pharmacy and a Master’s Degree in Public Health (University of Barcelona). He previously was the Head of Division of Pharmaceutical Care and Complementary Services, Catalan Health Service. Before that, he was responsible for Pharmaceutical Control and Drug Information. He had different positions, as a pharmacist in the Pharmaceutical Planning Service, as a researcher in pharmacology (Ferrer Internacional S.A. laboratory), and in immunology (Pharmacy Faculty, University of Barcelona). He is now the Director of Pharmacy Management and Pharmacoeconomics, Catalonia Health Department.

Nikos Maniadakis Associate Dean, National School of Public Health, Greece Nikos Maniadakis is a Professor of Health Services Organisation and Management and Associate Dean of the National School of Public Health in Greece. He studied Economics at the University of Athens, Health Economics at the University of York and Business Administration at Warwick Business School. Mr Maniadakis started his career as a Research Fellow at the Health Economics Research Centre of Oxford University and then moved on to take leading international positions in the pharmaceutical and the health care industry.

Conference 19


The new European Union platform for the promotion of self-care systems

In order to make progress in the wide promotion of self-care, a close coopera-tion with all relevant stakeholders is a key prerequisite. Such cooperation has become far more intensive over the last years and is now supported and facili-tated by the new European Union (EU) project on the promotion of self-care sys-tems, which is an extension of the work on good governance of non-prescription medicines carried out under the mandate of the previous European Commission. The session will give an update of the new EU project and discuss how to make the new platform relevant for the European citizens.

– Rosa Suñol, Director General, Avedis Donabedian Institute, Barcelona

– Birgit Beger, Secretary General of the Standing Committee of European

Doctors (CPME)

– Cristina Cabrita, Senior Project Officer, Portuguese Consumer Organisation (DECO) on behalf of the European Consumer Organisation (BEUC)

– Carmen Peña, President, International Pharmacists Federation (FIP)

Session 4

16:00-17:30


17:30 End of 1st day

20 Conference


Biographies

Birgit Beger Secretary General of the Standing Committee of European Doctors (CPME). Birgit Beger is a registered lawyer in Berlin and Brussels and holds degrees in law and political science from the Freie Universität Berlin. She has been working for over ten years in Public Affairs and Law in Brussels, inter alia with the European Parliament, a law firm and a European Umbrella Organisation in the area of human rights and social policy. Before her position as CPME Secretary General, Ms Beger was Senior Legal advisor at the Council of Bars and Law Societies of Europe (CCBE) responsible inter alia for Information Technology Law and European Contract Law.

Conference 21

Rosa Suñol Director General, Avedis Donabedian Institute, Barcelona Rosa Suñol is the Director of Avedis Donabedian Institute Autono-mous University of Barcelona (FAD). She is also the Deputy Editor of the International Journal for Quality in Health Care since 1991. She has published several articles and books and has over 25 years of experience in health and social care research on quality of, as well as implementing more than 230 internal quality programs in Spain. Ms Suñol has participated in several EU funded research projects such as MARQuIS and DUQuE and she co-ordinates the EU project “EMPATHIE”: Empowering patients in the management of chronic diseases”.


Biographies

Cristina Cabrita Senior Project Officer, Portuguese Consumer Organisation (DECO) on behalf of the European Consumer Organisation (BEUC) Pharmacist by training, Cristina Cabrita holds a Master in Public health in the field health promotion and education and finishing a Master in Epidemiology. Cristina joined the Portuguese Consumer Organization (DECO) in 2004. As senior project officer at DECO Cristina has daily contacts with consumers and provides them with information and advice on health related issues. Cristina represents DECO in relevant fora at national level and also represents the Euro-pean Consumer Organization (BEUC) at EU level (e.g. European Medicines Agency Pharmacovigilance Committee).

Carmen Peña

President, International Pharmacists Federation (FIP)

Carmen Peña is a Spanish pharmacist. She was elected President of the International Pharmaceutical Federation (FIP). As a commu-nity pharmacist from Madrid, Ms Peña has served FIP for more than 20 years, including being Vice-President since 2008. She is currently president of the General Pharmaceutical Council of Spain. Ms Peña, who is the first woman and first pharmacist from Spain to be elected as President in the FIP’s 102-year history, took office on 5 September 2014 for a presidency term of four years.

22 Conference


15:30-16:00 Break

Conference 23

Self-care medical devices and food supplements: New drivers for the self-care market?

Substance-based, self-care medical devices and food supplements have become an important part of self-care. However, their regulatory future is uncertain. The current revision of the medical device legislation addresses the adequate future legal basis for substance-based medical devices with different approaches under consideration. In the area of food supplements, the evaluation of botanical claims continues to be put “on hold” with uncertainties for the whole marketplace inclu-ding in particular herbal medicinal products, for which an elaborated system has been put in place in the European Union. The session will give an overview on where the debate stands and what the likely future environment will be.

– Hubertus Cranz, AESGP Director General

– Valeriu Curtui, Head of the Nutrition Unit, Head of the Nutrition Unit, European Food Safety Authority (EFSA)

– Gwenole Cozigou, Director, DG GROW, European Commission

– Werner Knoess, Chair, Herbal Medicinal Products Committee (HMPC),

European Medicines Agency (EMA)

Session 5

09:00-10:30

Thursday 28 May 2015


Biographies

Hubertus Cranz Director General, AESGP Hubertus Cranz has Masters’ degrees in Pharmacy and Econom-ics and obtained a Doctorate in Natural Sciences at the Universi-ty of Kiel, Germany. After taking part in different trainee pro-grammes in pharmacies and the pharmaceutical industry (Ciba, Bayer), he worked for the Institute for Health System Research in Kiel, a collaborating centre of the World Health Organization (WHO), and for the German Association of the Pharmaceutical Industry (BPI) in Frankfurt. Afterwards, he became Director Gen-eral of AESGP and established an organization in Brussels repre-senting the full range of the European consumer health industry.

24 Conference

Valeriu Curtui Head of the Nutrition Unit, European Food Safety Authority (EFSA) Valeriu Curtui holds a PhD in Veterinary Medicine, and his teaching and research activity focused on toxicology and chemi-cal food safety. Prior to his employment with the European Food Safety Authority (EFSA), he was an academic at the Justus Liebig University in Giessen (Germany) and at the University of Agricul-tural Sciences and Veterinary Medicine of Timisoara (Romania). Valeriu joined EFSA in 2008 as a scientific officer working on che-mical occurrence in food and dietary exposure and took up his current role as Head of the Nutrition Unit in 2013. His role is to manage the Unit in providing scientific and administrative sup-port to the EFSA Scientific Panel on Dietetic Products, Nutrition and Allergies (NDA Panel). The NDA Panel deals with questions related to dietetic products, human nutrition and food allergies as well as associated subjects such as scientific substantiation of health claims and safety of novel foods.


Biographies

Gwenole Cozigou Director, DG GROW, European Commission An economist by training, Gwenole Cozigou has been an offi-cial in the services of the European Commission since 1985, primarily in the fields of Enterprise and Industrial Policy and of External Relations. He was Deputy Head of Office of Commissioner Liikanen and occupied several management positions in the following areas: - Food Industry and Biotechnology; - Coordination of the internal market legislation for goods; - Enterprise and Industrial policy; - Defence, Aerospace and Maritime Industries. In 2008, Mr Cozigou was the Director for Chemicals, Metals, Mechanical, Electrical and Construction Industries, Raw Mate-rials, in the European Commission Enterprise and Industry Directorate-General. This included the industrial policy for pharmaceuticals. After the reorganisation of this Directorate-General in 2014, his reponsibilities also cover the area of medi-cal devices.

Werner Knoess Chair , Herbal Medicinal Products Committee (HMPC), European Medicines Agency (EMA) Werner Knoess studied Biology with a Diploma thesis on Natural products in marine algae in 1986. His postgraduate studies were at the Institute for Pharmaceutical Biology at the University of Bonn. He is Head of the Department Complementary and Alterna-tive Medicines and Traditional Medicinal Products at the Federal Institute for Drugs and Medical Devices, Bonn, Ger-many and Chair of the European Medicines Agency’s Com-mittee for Herbal Medicinal Products (HMPC).

Conference 25


Background information

Food supplements Food supplements are concentrated sources of vitamins and minerals and ‘other substances’ with a nutritional or physiological effect, marketed in dose forms. The purpose of food supple-ments is to supplement the normal diet to compensate possible nutritio-nal deficits.

At the European level, the adoption of Food Supplements Directive in 2002 created a legal basis for food supple-ments, providing general advertising and labelling principles as well as list-ing vitamins and minerals and their sources authorised in food supple-ments. For the time being, important ele-ments for this market place remain within the national responsibility, in-cluding minimum and maximum levels of vitamins and minerals, and the per-mission to use ‘other substances’, i.e. substances other than vitamins and minerals such as herbals, fatty acids, amino acids, probiotics. Nutrition and health claims on food and food supplements in the EU Food supplements are regulated in the EU as food and must comply with a legislative framework applicable to foods.

This includes in particular the legal provisions on nutrition and health claims which are often used in label-ling, advertising and promotion of food supplements and other foods. The EU Claims Regulation was adopted in 2006 aiming to protect the consum-er from misleading or inaccurate claims but also to allow the industry to use truthful and scientifically substanti-ated claims as a competitive marketing tool. In the EU, food supplements can-not bear claims unless they are author-ised. In order to get an EU authorisation, all health claims must be submitted to EFSA to undergo scientific assessment carried out by the EFSA Scientific Panel on Dietetic Products, Nutrition and Allergies (NDA). A health claim dossier shall include information on food char-acteristics, health relationship, condi-tions of use and pertinent scientific data which form the basis for the sub-stantiation of a claim. Following a scientific assessment by EFSA, health claims are authorised by the European Commission and the EU Member States. The authorisation de-cision is then subject to the scrutiny of the European Parliament and the Council. Authorised and non-authorised claims are published in the Official Journal of the EU and in the on-line EU Register of Claims.

26 Conference



EU definitions of nutrition and health claim made on foods and food supplements

Nutrition claim A claim suggesting that a food has particular beneficial nutritional properties due to:

it provides/ provides at a reduced or increased rate/ does not provide, e.g. ‘low energy’, ‘energy reduced’, ‘energy-free’

or other substances it contains/ contains in reduced or increased propor-tions/ or does not contain, e.g. ‘source of omega-3 fatty acids’, ‘low fat’, ‘sugars-free’

Health claim A claim suggesting that a relationship exists between a food and health

General function claim A health claim referring to the role of a nutrient in growth, development and the functions of the body, psychological and behavioural functions, slimming or weight control, e.g.:

General function claims are based either on generally accepted scientific evidence or on newly developed scientific evidence

Reduction of disease risk claim A health claim stating that the consumption of a food significantly reduces a risk fac-tor in the development of a human disease, e.g.:

a risk factor in the development of coronary heart disease’

Children claim A health claim referring to children’s development and health, e.g.:

EFSA NDA Panel scientific assessment of health claims applications

Conference 27



Medical devices Substance-based medical devices in-clude devices such as nasal sprays pri-marily used on sufferers, often infants with cold symptoms and blocked nose, denture adhesives, dentifrices for sen-sitive teeth, verruca and wart removers, gels for vaginal discomfort, lozenges to treat throat discomfort, flushing solu-tions, creams used to treat or prevent minor skin irritations, anti-snoring sprays, or anti-flatulence products act-ing by a chemico-physical mode of action. They are currently placed in the market in accordance with the essen-tial requirements of Directive 93/42/EC on medical devices. European Commission In September 2012, the European Commission proposed two new regu-lations on medical devices and on in vitro medical devices, with the inten-tion of replacing the existing legal framework for Medical Devices Direc-tives. The proposal suggested a new rule in the Annex VII “Classification crite-ria” Devices that are composed of substances or combination of substances intended to be ingested, inhaled or administered rectally or vagi-nally and that are absorbed by or dis-persed in the human body are in class III” (rule 21) and a point 9.2 of the annex I “General safety and perfor-

mance requirements”compliance of these devices with the relevant requirements laid down in Annex I to Directive 2001/83/EC on medicinal products. European Parliament

Under the ordinary legislative proce-dure, the European Parliament and the Council (Member States) examine the Commission’s proposal and have the possibility to introduce amendments to it. The European Parliament’s Committee for the Environment, Public Health and Food Safety, lead Committee on this file, started discussing the proposed regulations in 2012. The first reading position of the European Parliament was adopted in a plenary session in April 2014 under the rapporteurship of Dagmar Roth-Behrendt. Amongst others, the report proposes the deletion of Rule 21 in Annex VII, and of the reference to Annex I to Di-rective 2001/83/EC on medicinal prod-ucts. A new European Parliament’s negotiat-ing team led by the Member of the European Parliament and new rappor-teur on the file Glenis Willmott (UK) was appointed further to the European Parliament’s election in May 2014.

28 Conference



As of May 2015, the Council Working Party is still discussing provisions re-lated to Rule 21. No conlusion has been reached yet. Next steps

The aim of the Latvian EU Presidency is to reach a general agreement on the proposed regulation prior to the end of its term by the end of June 2015. So-called trilogue discussions on a compromise between the European Parliament, the Council of the European Union (Member States) and the Com-mission could possibly start under the Luxembourg Presidency of the EU (from 1 July 2015 to 31 December 2015). Once adopted and published in the Official Journal, the regulations will be directly applicable in all EU Member States. No further implementation pro-cess will be needed.

Conference 29

Council of the EU (Member States)

The Council has been examining the proposed regulations under the leader-ship of the latest six Presidencies of the Council of the European Union, respec-tively Cyprus, Ireland, Lithuania, Greece, Italy, and Latvia. The Council’s prepara-tory body in charge of the file is the Working Party on Pharmaceuticals and Medical Devices composed of representatives of the 28 Member States’ Ministries of Health/ National Competent Authorities. New provisions on substance-based medical devices proposed by the Latvi-an Presidency were discussed and ex-amined by the Committee of Perma-nent Representatives (COREPER) in March 2015, however not adopted. These included the following Rule 21 wording: Devices that are composed of sub-stances or combinations of substances

intended to be

and that are absorbed by or dispersed in the human body are:

In class III


Switching: A mega trend?

Is the move of medicines from prescription to non-prescription slowing down or speeding up? How important is it for the future of self-care? What needs to be done to be successful? These are key questions for many executives in the consumer health industry. The session will follow up on the 2014 London conference and expose recent positive developments and what needs to be done to keep the momentum.

– Suneet Varma, President, Consumer Healthcare, Pfizer

– Erin Gainer, Chief Executive Officer, HRA Pharma

– Darragh O’Loughlin, President, Pharmaceutical Group of the

European Union (PGEU)

– Belén Crespo, Agency for Medicinal Products and Medical Devices, Spain

Session 6

10:30-12:30


12:30-14:00 Lunch

30 Conference


Suneet Varma President, Consumer Healthcare, Pfizer Suneet Varma received his Master of Business Administration from the Harvard Business School and a Bachelor of Science in Engi-neering from Tufts University. Since joining American Home Prod-ucts Corporation in 1993, Mr. Varma has worked in consumer healthcare, prescription pharmaceuticals and the corporate head-quarters of the company. Most recently he was Regional Presi-dent, North America, for Pfizer Consumer Healthcare. His previous roles include Regional President, Asia Pacific and President of Pfizer Consumer Healthcare in Canada. In all his roles, Suneet has been a champion of consumer access to innovative self-care prod-ucts. Mr. Varma served on the boards of the Consumer Healthcare Products Association (CHPA) and the World Self-Medication In-dustry (WSMI). He is now President and General Manager of Pfizer Consumer Healthcare, and is responsible for all aspects of the business unit’s global operations.

Erin Gainer Chief Executive Officer, HRA Pharma Erin Gainer holds a bachelor's degree in biology and in English and a master's degree in public health. She has a Ph.D. in epidemiology from the University of Paris XI and completed her MBA for Execu-tives at INSEAD. Erin Gainer has been HRA Pharma's Chief Executive Officer and President of the Executive Board since 2009. Erin joined HRA Phar-ma in 2000 to lead the development of the new chemical entity, ulipristal acetate through the EMA and FDA approval processes. As Executive Director of Research and development, she built the company's crossdisciplinary R&D capacities up from the ground.

Biographies

Conference 31


Biographies

Darragh O’Loughlin President, Pharmaceutical Group of the European Union (PGEU) Darragh O’Loughlin graduated in 1993 from a School of Pharma-cy. After university, he worked in hospital pharmacies and in community pharmacy. He has operated his own pharmacies for the last fifteen years. He is currently the President of the Pharma-ceutical Group of the European Union (PGEU), having been its Treasurer since 2013. Darragh is Secretary General of the Irish Pharmacy Union since 2013 and was previously its President (2010 – 2012). He has also previously served on both the Board of the Health Information & Quality Authority (HIQA) in Ireland and the Council of the Pharmaceutical Society of Ireland (PSI), having been appointed by successive Irish Ministers for Health.

Belén Crespo Agency for Medicinal Products and Medical Devices, Spain Belén Crespo holds a Masters degree in Health Administra-tion and a Bachelor of Sciences in pharmacy. She has been Executive Director of the Spanish Medicines Agency since 2010. She previsouly held different positions such as: Deputy Director of Alert System and Official Controls at the Spanish Food Safety and Nutrition Agency; Head of Area of Pharmacy Management in Primary Attention; Head of the Department of the Studies and Control of the Offer of Medicines and Effects and Accessories, and Pharmaceutical Inspector at the National Institute of Public Health Care, Central Services in Spain.

32 Conference


How to ensure availability of safe products?

Over the last years, there has been an unprecedented increase in discussions about safety issues on the European level, the so-called referral procedures. Questions were raised as to whether all these procedures are justified and if they do not unnecessarily question existing products and hamper the move to non-prescription status. The session will also look at the intensive ongoing work in relation to the implementation of the directive on falsified medicines with poten-tially considerable implications in the marketplace.

– Vincent Warnery, Senior Vice President, Global Consumer Healthcare

Division, Sanofi

– Natalie Gauld, Director, Pharmacy Projects and Alison van Wyk, Professional Services Manager, Green Cross Health, New Zealand

– Sarah Branch, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

– Belén Escribano, Agency for Medicinal Products and Medical Devices, Spain

– Stefano Soro, European Commission

Session 7

14:00-15:45


15:30-16:00 Break

Conference 33


Vincent Warnery Senior Vice President, Global Consumer Healthcare Division, Sanofi After graduating from the Ecole Superieure des Sciences Economiques et Commerciales in 1991, Vincent Warnery joined Procter & Gamble France where he took on various marketing responsibilities. In 1996, he joined L’Oreal where he spent the next 15 years. After a promotion to Europe Marketing Director Garnier/Maybelline in 1998, he took over several General man-agement responsibilities in Portugal, Germany, Latin America and Japan. He came back to France in 2008 and took over the responsibility of L’Oreal Paris France and later L’Oreal Cos-metique Active Division. He joined Sanofi as Vice President Con-sumer Health Care Europe and Global Development in 2011.

Natalie Gauld Director of Pharmacy Projects, former member of the New Zea-land, Medicines Classification Committee A pharmacist by background, Natalie Gauld has worked in community pharmacy, industry, research and education and obtained a PhD examining why countries vary in prescription to non-prescription switch of medicines. She was a member of the New Zealand Medicines Classifica-tion Committee from 2004-2009 and has subsequently driven switches in New Zealand in influenza vaccination and the first-in-world switches of calcipotriol and trimethoprim. Today, she is the director of Pharmacy Projects.

Alison van Wyk Professional Services Manager, Green Cross Health

Alison van Wyk is a nurse and work in sales, marketing and country management in both the pharmaceutical and medical device market both in New Zealand and internationally. Further to that she has eight years experience in the New Zealand pharmaceutical and medical logistics industry. Alison together with Natalie Gauld from Pharma Projects recently won the clini-cal services of the year award at the 2013 Pharmacy Awards. Alison joined the Pharmacybrands business in October 2010.

34 Conference

Biographies


Biographies

Sarah Branch Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom Sarah Branch has worked at the Medicines and Healthcare products Regulatory Agency (MHRA) and its predecessor, the Medicines Con-trol Agency, for over 20 years after lecturing in Pharmacy at the Uni-versity of Bath, UK. She is a qualified pharmacist and has previously assessed pharmaceutical aspects of new licence applications. She moved into management in 2001, initially looking after a team res-ponsible for licence variations but then with broader roles in the Division responsible for pharmacovigilance. Sarah continues to ma-nage the team responsible for paediatric procedures under the EU Regulation and is now Deputy Director of the Vigilance and Risk Management of Medicines Division.

Belén Escribano Agency for Medicinal Products and Medical Devices, Spain Belén Escribano holds a PhD in Pharmacy and a degree in Hospital Pharmacy, as well as a Masters in Public Health. After working in the National Health System as an hospital pharmacist, she moved to the Health and Consumers Affairs Department of the Regional Govern-ment of Madrid. Then, she moved to the Spanish Agency for Medici-nal Products and Medical Devices (AEMPS), and since then has been responsible for its Pharmaceutical Inspection and Enforcement De-partment. Nowadays she is the Head of the Pharmaceutical Inspec-tion and Enforcement Department of the AEMPS. She is also actively involved in the implementation of the falsified medicines directive at national level.

Stefano Soro European Commission Stefano Soro holds a degree in Management and Economics with a major in human resources management from Università Bocconi in Milan. Mr Soro joined the European Commission in 1994, serving succes-sively in a variety of posts in labour statistics, enterprise policy, in-ternal coordination and Commission reform. In 2002, he moved to the Consumer Affairs Directorate. In September 2006, Stefano Soro was appointed Head of the "Product and service safety" unit, re-sponsible for non-food consumer safety issues. He is today Head of Unit “Medicinal Products - Quality, Safety and Efficacy” at the Direc-torate General Health and Food Safety

Conference 35


36 Conference

Perspectives for the future

The final session will allow a discussion on the future of citizen empowerment and selfcare with a focus on the priorities of the new European Parliament in the given context.

Session 8

16:15-17:15


– Roger Scarlett-Smith, AESGP President

– Peter Liese, Member of the European Parliament

– Noel Wathion, European Medicines Agency (EMA)

17:15

Invitation to the 52nd AESGP Annual Meeting 31 May – 2 June 2016 in the Divani Apollon Hotel, Vouliagmeni, Athens, Greece

– George Dokios, Executive Director, Association of the Greek Self-Care Industry, EFEX, Greece


Roger Scarlett-Smith President AESGP, GSK Consumer Healthcare Roger Scarlett-Smith graduated with a Master in Law from St. John’s College, Cambridge University. He started his career as a graduate recruit in marketing at Procter and Gamble. He joined GlaxoSmithKline Consumer Healthcare in 1984. His roles included running the Consumer Healthcare businesses in the UK, Australia and New Zealand as well as North America, and Europe. He also served as President of the Proprie-tary Association of Great Britain (PAGB). He has been serving as Presi-dent of AESGP since July 2014.

Peter Liese Member of the European Parliament Peter Liese has a doctorate in medicine from the Institute of Human Genetics at Bonn University. He worked in Central America (public hospital and development aid projects). He became a local councilor in Bestwig (Germany) in 1989 and he was elected as Member of the European Parliament in 1994. During his terms in the European Parliament, he was appointed chairman of the bioethics working party of his political group EPP (European Peoples Party), and EPP-Coordinator in the Committee on the Environment, Public Health and Food Safety.

Biographies

Conference 37


Biographies

George Dokios

Executive Director, Association of the Greek Self-Care Industry, EFEX

George Dokios started his career as a sales representative in Bristol-Myers Squibb (then Bristol Myers) and rose through various key business positions to become the General Man-ager of Pharmaceuticals in the same company. In 1995, he became the General Manager in Portugal where he served for six years, before acquiring the same position in Greece. In 2004, Mr Dokios became the Director General of the Greek Association of Self-Medication Industry (EFEX).

38 Conference

Noel Wathion European Medicines Agency (EMA) Noël Wathion is a qualified pharmacist from the Free Univer-sity of Brussels. He first worked as pharmacist in a retail pharmacy. He was later appointed to the Pharmaceutical Inspectorate (Ministry of Social Affairs and Public Health) in Brussels as a Chief Inspector. He is a former Belgian Member of both the CPMP (Committee for Proprietary Medicinal Pro-ducts) and CVMP (Committee for Veterinary Medicinal Pro-ducts), and representative on the Pharmaceutical Committee, Standing Committee and Notice to Applicants working group. He joined the EMEA (European Medicines Evaluation Agen-cy) in 1996 as Head of Sector for Regulatory Affairs and Pharmacovigilance and was then appointed Head of the Human Medicines Evaluation Unit. Further to the restructu-ring of the Unit in 2001, he was appointed Head of Unit for the Post-Authorisation Evaluation of Medicines for Human Use. Then following a restructuring of the EMA in 2009, he was appointed Head of Patient Health Protection. He is now Chief Policy Adviser.


Closing event


The conference will end with a dinner at the restaurant Barceloneta

18:30

Departure of buses from the Hotel Hilton Diagonal Mar

19:00

Dinner at the Restaurant Barceloneta

From 21:45 onwards

Return by buses

Dress code: Business casual

Conference 39


Social programme


The guided tour for accompanying persons will take place on Wednesday, 27 May 2015. The tour bus will depart from the Hilton Diagonal Mar at 9.00 hours and will return at 17.00 hours. In the morning, participants will visit the premises of Codorniu, famous for its Cava. Lunch will be served there. This will be followed by a visit of “Gothic Barcelona”: the Cathedral, Town Hall and Santa Maria del Mar. Participants will be accompanied by an English speaking guide.

40 Conference


Next AESGP conferences14-15 October 2015

Renaissance Hotel Brussels

Substance-based medical devices: An important part of self-care

The AESGP Conference on self-care medical devices will take place atthe Renaissance Hotel in Brussels on 15 October 2015, in conjunction with the AESGP Annual Reception at the European Parliament on 14

October 2015.

Decision makers and high level representatives of public and regulatoryauthorities will join industry experts and representatives of other

stakeholder groups at the event to review latest developments and discuss next steps for the sector.

More information available on aesgp.eu/BRU15

15-16 February 2016 Amsterdam

AESGP Conference with the EU Heads of Medicines

Agencies (HMA) during the Dutch EU Presidency

Conference 41


Cae

I‘ccie

Df

The AESGP Data Bank is an online database that includes information previously found in the AESGP studies “Economic and Legal Framework (ELF) for non-prescription medicines” and “Legal and regulatory Framework for Herbal Medicines”.

med.aesgp.eu

Medicines and Medical Devices Data Bank

42 Conference


Information for the European Union with applicable European legislation is also included in the database. Table sub-sections for the European Union include by default applicable provisions in all EU member states.

Combined results appear by section and then by country (see for example image below). In specific sub-sections (denoted as ‘tables’ in the database), the combined search of more than one country will give aggregated results in a comparative table (see for example image below).

Database functionality

Conference 43


food.aesgp.eu

Food Supplements Data Bank

The AESGP Food Supplements Databank provides key information for the industry, national competent authorities and academia on the legal and regulatory framework for food supplements in Europe and beyond.

44 Conference


eu

Conference 45


List of participants

List of participants International organisations ADAMASZWILI, Kinga, Mrs AESGP BEGER, Birgit, Mrs CPME BERGSTRÖM, Richard, Mr EFPIA BESSON, Lucas, Mr EPSA BUA, Ornella, Ms AESGP CABRITA, Cristina, Mrs BEUC CHAVE, John, Mr PGEU CHINOU, Ioanna, Prof. Dr EMA COZIGOU, Gwenole, Mr European Commission CRANZ, Hubertus, Dr AESGP CURTUI, Valeriu, Mr EFSA DERECQUE-POIS, Monika, Mrs GIRP DZIEKAN, Gerald, Dr WSMI GITS, Lucy, Mrs AESGP JENNY, René, Mr GIRP KNÖSS, Werner, Prof. Dr EMA LIESE, Peter, Dr European Parliament MOUSSA, Miranda, Ms AESGP O’LOUGHLIN, Darragh, Mr PGEU PEÑA, Carmen, Mrs FIP ROTH-BEHRENDT, Dagmar, Mrs Former Member of the European Parliament SCARLETT-SMITH, Roger, Mr AESGP President SORO, Stefano, Mr European Commission TERBERGER, Martin, Dr AESGP WATHION, Noël, Mr EMA

Algeria BENBAHMED, Lotfi, Mr Conseil de l’Ordre des Pharmaciens BENHAMDINE, Farid, Dr Société Algérienne de Pharmacie BENMAKHLOUF, Majid, Mr Ministry of Health YOUBI, Mustapha, Mr Sanofi

Australia SCHOOMBIE, Deon, Dr ASMI

Austria BUCHEBNER, Christine, Dr GfK Austria EIBEGGER, Susanne, Mrs Bayer Austria FREY, Denise, Ms Kwizda Pharma GROTTENTHALER, Ulrich, Mr Boehringer Ingelheim GRÜN, Alfred, Mag. Schuelke & Mayr LÖTSCH, Gerhard, Dr IGEPHA NAGELER, Christina, Mrs & Mrs Erika SANDER IGEPHA PEITHNER, Martin, Mr Austroplant PEROUTKA, Günter, Mr Mag. G. Peroutka SANDOR, Stephen, Mr Kwizda Pharma SCHNEIDER, Peter, Mr Austrian Health Institute WELLAN, Max, Mr Austrian Chamber of Pharmacists ZOLLER, Martin, Mr Boehringer Ingelheim

Belgium CASSIMAN, Jan, Mr Oystershell CORONEL, Mary, Mrs DE BAERDEMAEKER, Jurgen, Mr IM Associates

51st AESGP Annual Meeting Barcelona 26-28 May 2015

46 Conference



GALAND, Frédéric, Mr Promomed MARANES, Gustavo, Mr Johnson & Johnson MERTENS, Gilbert, Mr Consultant RAEMDONCK, Noëlle, Mrs Promomed TEMPRA, Alessandro, Mr Johnson & Johnson VAN REETH, René, Mr BACHI VANDIEST, Philippe, Mr Promomed VERHAGE, Bert, Dr Will-Pharma VERLINDEN, Marc, Mr Qualiphar WILL, Maurienne, Mrs Will-Pharma

Brazil MARQUES NETO, Jonas, Mr ABIMIP

Bulgaria PIEROVA, Mihalea, Mrs Sanofi-aventis

Canada PROUD, Karen, Ms Consumer Health Products Canada SKINNER, David, Mr & Mrs Karen PATRICK Heuristix

Croatia TODORIĆ-KOVAČEVIĆ, Vesna, Mrs Belupo

Czech Republic MELNYK, Nick, Mr Sanofi

Denmark NOERUM, Helle, Ms Fertin Pharma

Egypt ABDELLATIF, Yasser, Mr Ministry of Health GHADA, Michel, Mr Sanofi HUSSIEN, Mearal, Mrs GlaxoSmithKline Consumer Healthcare MOHAMED, Aml, Mr Ministry of Health NAZMY, Noha, Mr Sanofi

Finland DELTORT, Didier, Mr GE Healthcare GOHLKE-KOKKONEN, Maija, Ms PIF VERTANEN, Janne, Mr Oy Verman

France ANTONIO, Manuel, Mr Celtipharm BACOS, Jean-Claude, Mr Bristol Myers Squibb BERTRAND, Mireille, Mrs Sanofi BON, Antoine, Mr Urgo BROCHET, Benoit, Mr Naturex BROSSARD, Pascal, Dr Zambon BULIDON, Valerie, Dr Sanofi-aventis BURZACCA, Giulio, Mr Sanofi CAUDWELL, Amanda, Mrs Sanofi CHETCUTI, Irène, Mrs Boiron DE LA FOUCHARDIÈRE, Christophe, Mr Sanofi DECHELETTE, Lionel, Mr Pierre Fabre DERRE, Jean-François, Mr Celtipharm ERWIN, Cathy, Mrs Sanofi FLACHAIRE, Magali, Mrs RB GAINER, Erin, Dr HRA Pharma GEORGAKOPOULOS, Evangelos, Mr Pfizer Santé Familiale GUILLARD, Hélène, Mrs HRA Pharma

Conference 47



HELLNER, Dirk, Mr Sanofi HIRT, Eva, Mrs Sanofi INFESTA-FERNANDEZ, Josep, Mr Sanofi LECOMTE-SOMAGGIO, Daphné, Mrs AFIPA MAGLIONE, Sandrine, Mrs AFIPA MAILLARD, Eric, Mr Tonipharm OSSENBERG-ENGELS, Dirk, Mr Bayer HealthCare PEYRICAL, Bernard, Mr Sanofi PRISMICH, Glaucia, Mrs Sanofi-aventis PRZYBYLSKI, Christoph, Mr Pierre Fabre TEO, Eric, Mr Sanofi UBAYSI, Kamal, Mr Sanofi VAN RYCKE, Isabelle, Mrs Sanofi-aventis VAUCEL, Fabien, Mr Sanofi VOISIN, Sophie, Mrs Sanofi WARNERY, Vincent, Mr Sanofi WELGRYN, Frédérique, Mrs HRA Pharma

FYROM STOJANOV, Orce, Mr Alkaloid VELEVSKA, Aleksandra, Mrs Alkaloid

Germany AKBABA, Metin, Mr Bayer Pharma BURGES, Johannes, Mr & Ms Marietta Hermes Arzneimittel BUSSE, Werner, Dr Dr. Willmar Schwabe CARTER, Paul, Dr Boehringer Ingelheim CASPAR, Susanne, Mrs Schaper & Brümmer CSOKE, Emese, Dr Boehringer Ingelheim DETHLEFFSEN, Andreas, Mr & Mrs Christiane Queisser Pharma DITTRICH, Heinz, Dr & Mrs Andrea Bad Heilbrunner DITZEL, Peter, Mr & Mrs Reinhild BERGER Deutsche Apotheker Zeitung FREUDENSTEIN, Johannes, Dr Boehringer Ingelheim GRAF, Angela, Dr BAH HARTLEY, Alison, Mrs Boehringer Ingelheim HOFFMANN, Tino, Mr Helm Medical HOLLSTEIN, Patrick, Mr Apotheke Adhoc KÄSTNER, Uta, Dr RB KEBIG, Anna Elisabeth, Dr Bayer Vital KOCH, Johannes, Mr BAH KOEPFER, Bärbel, Mrs Koepfer time-to-market KOLKMANN, Rainer, Dr Diapharm KORTLAND, Hermann, Dr BAH KRABICHLER, Gert, Dr MerckSelbstmedikation KROTH, Elmar, Dr BAH KUNZ, Stephanie, Mrs BAH KUSKOWSKI, Jan, Mr & Ms Tina Queisser Pharma LASCHET, Helmut, Mr Ärzte Zeitung LORENZ, Raoul, Mr Lorenz Life Sciences Group MEYER, Stefan, Mr Bayer Vital MIROW, Roland, Mr ATKearney MÜCKE, Miriam, Mrs Helm Medical OEHMICHEN, Alexander, Dr & Mrs Anja Dr Oehmichen & PartnerMANDELKOW PETERSEN-BRAUN, Marianne, Hermes ArzneimittelDr & Mr Joachim BRAUN PROPPERT, Maximilian, Pharma-Labor Yvonne ProppertMr & Mrs Maike GOFFART PROPPERT, Yvonne, Mrs Pharma-Labor Yvonne Proppert REGENAUER, Hans, Mr & Mrs Rosemarie HVR-Advice REINERT, Wolfgang, Mr BAH

48 Conference



REISCHIG, Dirk, Dr Dr Willmar Schwabe SANDNER, Stefan, Dr & Mrs Sabine Diapharm SCHEIFFERT, Michaela, Mrs Sanofi-Aventis SCHMICKLER, Heinz-Gert, Mr BAH SCHOETT, Erich, Mr Boehringer Ingelheim SCHREPFER, Andreas, Dr & Mrs Martina Hermes Arzneimittel SEIPP, Joachim, Mr Bauer Advertising SIBBING, Nicole, Mrs Diapharm SIBBING, Ralf, Mr Diapharm STEINHOFF, Barbara, Dr BAH STIER, Heike, Mrs analyze and realize TEBROKE, Ev, Mrs Pharmazeutische Zeitung ULLRICH, Traugott, Dr Dr. Willmar Schwabe UMLAND, Thorsten, Dr Bayer HealthCare WEISER, Martin, Dr BAH WIECZOREK, Joerg, Mr & Mrs Waltraut Hermes Arzneimittel WILKE, Lilian-Susan, Mrs Wort & Bild WINTER, Michael, Mr Egon Zehnder WITZEL, Wolfgang G., Mr Lorenz Life Science Group WRIGHT, David, Mr Boehringer Ingelheim

Greece DOKIOS, George, Mr Efex DOKIOS, Thomas, Mr EFEX MYLONAS, Charalampos, Mr National School of Public Health

Hungary CIBULYA-PALFAI, Gréta, Dr Gedeon Richter FÖLDHÁZI, Enikő, Dr Egis Pharmaceuticals SUGÀR, Dalma, Dr RB SZÖRÉNYI, Beáta, Mrs Sanofi

Israel UVAL, Avi, Mr Telem

Italy ALLIEVI, Enrico, Dr Assosalute CRICELLI, Claudio, SIMGDr & Mrs Nadia GIANMOENA GARLASCHINI, Renato, Dr Assosalute GAUDIOSO, Antonio, Dr Cittadinanzattiva GAUXACHS, Carmen, Mrs RB GIOVAGNONI, Emiliano, Dr Aboca GIULIANI, Gianfranco, Dr ACRAF LEOPARDI, Eugenio, UTIFARDr & Mrs Giada SPAGNUOLO LUPARINI, Maria Rita, Mrs E-Pharma Trento MAZZOTTA, Fabio, Mr Sanofi MERCATI, Valentina, Mrs Aboca PILLARELLA, Carla, Dr Assosalute REGNAULT, Agnès, Mrs Pfizer ZUCCHETTI, Luisa, Ms Angelini

Japan KOJIMA, Norihisa, Mr Kowa NAKAMURA, Takatsugu, Mr Taisho NARUSAWA, Takashi, Mr Kowa NISHIZAWA, Motohito, Mr Japan Self-Medication Industry (JSMI) SATO, Seiichi, Mr Sato Pharmaceutical TAGASHIRA, Yasuhiro, Mr APSMI

Conference 49



TANIKAWA, Masahide, Mr Kowa TSUTSUI, Mototsugu, Mr Taisho

Jordan AL-HADIDI, Iklas, Mr Food and Drug Authority BATARSA, Sohaila, Mrs Food and Drug Authority OBEIDAT, Ayel, Dr Food and Drug Authority

Lithuania CEKANAUSKIENE, Ausrine, Mrs Sanofi-aventis

Mexico BOLAÑOS, Héctor, Mr & Mrs Maria-Cristina Afamela

Morocco DERRAJI, Abderrahim, Mr Fondateur Pharmacies.ma EL MALHOUF, Naoufal, Dr Direction de l’ANAM ELKHALIFI, Omar, Mr Cooper Pharma LAMRANI, Rachid, Mr Pharmacie.ma

New Zealand GAULD, Natalie, Dr Pharmacy Projects ROPER, Richard Timothy, Mr NZSMI VAN WYK, Alison, Mrs Green Cross Health

Norway MAEHLUM, Marianne, Ms Takeda

Poland BLASZCZYK, Rafal, Mr RB BLASZCZYNSKI, Witold, Mr PASMI JURGAWKA, Robert, Mr USP KRUSZEWSKA, Magdalena, Mrs Nepentes Pharma SOCHA, Elzbieta, Ms PASMI

Portugal GAMINHA, Ana Beatriz, Dr BSG Pharmaceuticals

Republic of Korea LEE, Kyeong-Ho, Dr KPMA

Romania ROSIAN, Iulia, Mrs Sanofi-aventis

Russian Federation BOYTSOV, Vasily, Mr Eurasian Economic Commission EGOFAROV, Nail M., Mr GlaxoSmithKline Healthcare KILDYUSHKIN, Andrey, Mr Johnson & Johnson SHIPKOV, Vladimir, Mr & Mrs Nina SHIPKOVA AIPM

Serbia DJUROVIC, Dragan, Mr Medicines and Medical Devices Agency of Serbia

South Africa ZAROUDOUKAS, Natalie, Ms Adcock Ingram

Spain AGUADO, Carmen, Mrs Health Department Madrid Autonomous

Region AGUADO, Mayte, Ms anefp ALLENDE MONCLUS, Ana, Mrs Laboratorios Dr. Esteve

50 Conference



ALTEMIR, Javier, Mr Almirall ARAUJO, Maria, Mrs Uriach-Aquilea ARIZCUREN ZAPATER, Natalia, Mrs Chiesi ARRIOLA, Luis, Mr Europa Press AYO, Sonia, Mrs GSK Consumer Health Care BARELLI ARAGON, Miguel, Mr Boiron BARRIO, Luis, Mr Luba Consult BARZANO ABAD, Gema, Ms Esteve BASOLAS TENA, Maria Carmen, Mrs Chiesi BASORA, Josep, Mr SENFYC BOSCH, Alvaro, Mr PMFarma BROCAL, Naiara, Mrs Correo Farmacéutico BUENDIA SANCHEZ, Esmeralda, Mrs Arkopharma BUENO GALLEGO, Alberto, Mr Laboratorios Salvat CAMPOS, José, Mr Ferrer CAMPS MIRO, Mercedes, Ms GTF CARBONEL, Beatriz, Mrs FEFE CASSANY, Salvador, Mr GENCAT CASTELLÓ, Maria, Ms Johnson & Johnson CASTILLO, Jesús, Mr Gaceta Médica CLOSA, Maribel, Mrs Boehringer Ingelheim CRESPO, Belén, Dr Spanish Medicines Agency CUADRAS RAYMI, Elisa, Mrs Zambon DALMASES, Jordi, Mr COF Barcelona DE LA CUERDA, Angel Luís, Mr AESEG DE QUIROGA, Santiago, Mr El Global DEL OLMO, Patricia, Mrs Estar Bien DEL RIO CASADO, Javier, Mr CINFA DEMEURE, Thierry, Mr Sanofi DÍAZ MARCOS, Susana, Ms Boiron DÍAZ VARELA, Raul, Mr AESEG DOS RAMOS FARIAS, Martin, Mr Bayer Hispania ENDRÉNYI, Szilvia, Ms Gedeon Richter ESCALERA, Sonia, Mrs Lacer ESCRIBANO, Belén, Mrs Spanish Medicines Agency ESTEVE, Albert, Mr & Mrs Marina Laboratorios Dr Esteve ESTEVE, Antoni, Mr Farmindustria FERNANDEZ, Francisco, Mr Unidad Editorial FERRE, Piedad, Mrs Ministry of Health FERRER LOPENZO, Ana Maria, Ms Bayer Hispania FONT, Javier, Mr Fardi GALLARDO, Lucia, Mrs Informativo FEFAC GARCÍA VAQUERO, María Luisa, Mrs AEMPS GAVALDÁ, Josep, Mr COF Barcelona GILABERT, Antoni, Mr Catalan Health Service GÓMEZ, Jesús, Mr SEFAC HERNÁNDEZ, César, Mr AEMPS HORTELANO ALMEIDA, Felipe, Mr Angelini INFANTE, Filipe, Dr Health Market Research INIESTA, Cristina, Mrs Public Health Agency ISBERT, Carmen, Ms anefp JANÉ LLORET, Miguel Angel, Mr Almirall JUAN, Sonia, Mrs Boehringer Ingelheim LABORDA, Merce, Mrs CUS LÁCAR SALDÍAS, Beatriz, Mrs Cinfa LENS, Carlos, Mr Ministry of Health LOPEZ GIL, Meritxell, Mrs Lab. Dr Esteve LÓPEZ, Pilar, Mrs GENCAT LÓPEZ-GIL, Maite, Ms anefp MADRID, Paloma, Ms GlaxoSmithKline Consumer Healthcare MARCH, Javier, Mr El Farmacéutico

Conference 51



MARCOS, Rubén, Mr Europa Press MARTÍ, Arantxa, Mrs Farmaindustria MARTIN CORTÉS, Manuel, Mr Mylan EPD MARTÍN PADILLA, Silvia, Mrs Ferrer MARTÍNEZ MORA, María Luisa, Mrs AEMPS MASEGOSO ARTEAGA, Mª Pilar, Ms Almirall MASJUÁN, Mamen, Ms anefp MINGUELL FONT, Esther, Mrs Zambon MORENO, Sofía, Mrs Laboratorios Salvat NAVARRO OLIVELLA, Javier, Mr Uriach NORIEGA, Miguel, Mr HRA Pharma NUENO, Pedro, Prof. IESE Business School OLLEROS, Tomás, Grupo FarmasierraORTÍZ, Dr & Dr Mrs Ana Isabel PAPIOL, Cristina, Mrs Laboratorios Hartmann PATINHA, Marco, Dr Health Market Research PELLISÉ, Laura, Mrs CRES University Pompeu Fabra PÉREZ PEY, Marc, Mr Hartmann PEY, Jaume, Mr anefp RAMENTOL, Jordi, Mr Ferrer REDONDO, Fernando, Mr FEFE RIBADA GRANJA, Alicia, Dr Ferrer RICE, Katherine, Mrs CINFA RIESGO, Marta, Mrs El Global RIVERO, Agustín, Mr Ministry of Health RODRIGUEZ RIERA, Mariola, Mrs Lab. Dr. Esteve ROLDÁN, Tais, Mr RB ROVIROSA ESCOSURA, Mario, Mr Chiesi RUIZ, Boi, Mr Minister of Health Catalonia SÀBAT SANTANDREU, Eduard, Mr Angelini SALADA, Angel, Mrs IM Farmacias SANGLAS, Helena, Mrs IM Hospitales SANZ, Esther, Mrs Boehringer Ingelheim SANZ, Ferran, Prof. IMIM SARDÁ, José María, Mr Johnson & Johnson SASTRE, Nuria, Mrs anefp SEDANO MONASTERIO, Eugeni, Dr Dr. Esteve SERRA, Joan, Mr GENCAT SISTERNAS, Carlos, Mr Fenin SOLÍS, Raquel, Ms anefp SORIANO, Joan, Mr El Pais SUÁREZ, María Luisa, Ms AEMPS SUÑOL, Rosa, Mrs Avedis Donabedian Institute TORRES, Antonio, Mr FEFAC UROSA, Blanca, Mrs Health Department Madrid Autonomous

Region VENEGAS, Cecilio, Mr Consejo General de Farmacéuticos VILDA, Javier, Mr El Periodico VOSSOS, Konstantinos, Mr GlaxoSmithKline Consumer Healthcare ZABALA ALFONSO, Elena, Mrs Zambon

Sweden BERGLUND, Johan, Mr McNeil AB NÄSMAN, Inger, Mrs LIF

Switzerland ALEKXANDROVA, Ioulia, Novartis Consumer HealthMrs & Mr Christian SUBLET BANGERTER, Martin, Schweizerischer Drogistenverband (SDV)Mr & Mrs Judith BANGERTER-PAETZ BORRI, Michele, Mr Vifor

52 Conference



BUENNIG, Frank, Mr Medinova CSELOVSZKY, Kristina, Ms DSM Nutritional Products DELCKER, Andreas, Dr Galderma - Spirig FUHRER, Hans-Rudolf, Mr & Mrs Martha ASSGP GENÈVE, Sébastien, Dr Bayer Consumer Care GOETSCHMANN, Ursula, Ms Interdelta HARTMANN, Urs, Mr Bayer Consumer Care HÖCHNER, Peter, Mr HCI Solutions HÖLZLE, Walter, Mr vips HUBER, Elisabeth, Ms & Mr Stefan VON GRÜNIGEN Schweizerischer Drogistenverband (SDV) KANTSPERGER, Christine, Ms Bayer Consumer Care LEHMANN, Urs, Dr S imilasan MABBOUX, Bruno, Dr PGT Healthcare MENNET-VON EIFF, Mónica, Dr Weleda OHLE, Joerg, Mr Bayer Consumer Care PESTALOZZI, David, Mr & Mrs Gudrun Bio-Strath SCHAEFER, Ulrich, Dr HCI Solutions SCHORI, Beat, Mr Sanofi-aventis SCHUHBAUER, Birgit, Mrs Johnson & Johnson Consumer Europe SPÄNI, Daniel, Mr & Mrs Karina SCHILDKNECHT Sanatrend STÜDELI, Walter, Mr ASMC SUSLOVA, Vlada, Ms Bayer Consumer Care SZURAN, Thomas F., Dr Biomed TOMMASI ROSSO, Fabio, Mr Novintethical TREPP, Gian, Mr Similasan ZAIDAN, Fadel, Mr PGT Healthcare

The Netherlands ALBERTS, Nico, Mr Vemedia BALMER, Robert, Mr Medical Brands BEENAERTS, Greet, Mrs & Mr Guido LEYSSENS Bayer BOUWMEESTER, Vincent, Mr Medical Brands FEDOROVA, Victoria, Mrs Medical Brands FLUITMAN, Maayke, Mrs care2create GROEN, Dirk, Mr Meda Pharma HENDRIKS, Maikel, Mr Medical Brands HOOGENDOORN, Henry, Mr Tjoapack JONGERIUS, Rutger, Mr Archy Consulting LELIE-VAN DER ZANDE, Rian, Ms KNMP MAURITZ, Bernard, Mr Neprofarm VAN DIJK, Bauke, Mr Medical Brands VERSCHUUREN, Niels, Mr Patheon VU, Dzung, Ms RB

Tunisia BEN MOHAMED, Ahlem, Mrs Direction de la Pharmacie et du Médicament GARALI, Rached, Mr Syndicat des Pharmaciens JALLEL, Abdallah, Mr Conseil de l’ordre des Pharmaciens JERIBI, Chokri, Mr Sanofi KILANI, Rafik, Mr Teriak MASMOUDI, Sara, Ms Teriak

Turkey BAŞARAN, Ahmet, Mr Ministry of Agriculture ÇOLAK, Erdoğan, Mr Turkish Pharmacists Association KEKLIK, Huseyin Kagan, Mr Sanofi KıZıLAY, Harun, Mr Turkish Pharmacists Association SATıK, Devrim, Mr Sanofi SERBEST, Aslihan, Mrs Boehringer Ingelheim TATAR, Yavuz, Mr Turkish Pharmacists Association YUCEL, Erman, Mr Sanofi

Conference 53



Atunca

Foprtrahe

Wprorhuanch

GTN

Lin

United Arab Emirates ABDEL MALIK, Hany, Dr Boehringer Ingelheim KANDIL, Rasha, Mrs Mundipharma KHALIFA, Anas, Dr Public Health & Safety Department MOHSIN, Adi, Dr Bayer Healthcare SAWIRIS, Ramez, Mr GlaxoSmithKline Consumer Healthcare SHIYAB, Mejad, Mrs Bayer Healthcare

United Kingdom BASA, Ahmed, Mr Johnson & Johnson BASSI, Cristina, Ms RB BHATT, Aomesh, Dr RB BRANCH, Sarah, Dr MHRA BUCKELDEE, Robert, Mr nielsen CALDER-SMITH, Martin, Mr Communications International Group CALDWELL-NICHOLS, Matthew, Mr Communications International Group CARPENTER, Glenn, Dr & Mrs Janice Johnson & Johnson CARR, Alison, Dr Hamell Communications CARTER, Sarah, Ms OTC Insight Europe CASTLE, Donna, Mrs PAGB CHAMPION, Stephen, Mr GlaxoSmithKline Consumer Healthcare DARRACOTT, Helen, Mrs PAGB DUDLEY, James, Mr James Dudley International GALLEN, Tom, Mr OTC Bulletin GRIFFITHS, Mark B., Dr Pfizer Consumer Healthcare HALL, Nicholas, Mr Nicholas Hall HAMMOND, Fiona, Ms Hamell Communications HARTNETT, Owen, Mr Nicholas Hall KELLY, Sheila, Ms KINYUA, Chris, Mr Nicholas Hall NIETO, Francine, Mrs IMS Health O’BRIEN, Felim, Mr Communications International Group PEAD, Filomena, Ms Nicholas Hall PITALE, Prasanna, Mr IMS Health RICE, Mike, Mr OTC bulletin SCHESKE, Manfred, Mr infirst Healthcare SHEPHARD, Toby, Dr Pfizer SPEERS, Matthew, Mr PAGB STEWART, Matt, Mr OTC bulletin STIMSON, Nina, Mrs Nicholas Hall TISMAN, Andy, Mr IMS Health WILKES, Deborah, Mrs & Mr Alaric WATERSON OTCToolbox

United States of America CHILUKURI, Sastry, Mr McKinsey CLOUD DUGAN, Noelle, Mrs GlaxoSmithKline Consumer Healthcare COLGAN, Kevin, Mr Pfizer Consumer Healthcare COMBE, Christopher, Mr & Mrs Courtney Combe FIELDING, Jeanette, Mrs Bayer HealthCare KUSMIEZ, Katazyna, Ms US Pharmacia MCNAMARA, Brian, Mr GlaxoSmithKline Consumer Healthcare MELVILLE, Scott, Mr CHPA MURA, Raquel, Ms Sanofi MURPHY, William, Mr Johnson & Johnson OLOHAN, Ryan, Mr Google PAYAWAL, Mariclaire, Ms Pfizer Consumer Healthcare SPANGLER, David, Mr CHPA VARMA, Suneet, Mr Pfizer

Status 20 May 2015 (noon)

54 Conference


Contact Frances Shortland for an exploratory discussion at [email protected] or +44 (0) 207 534 7222

How well do pharmacists and health advisors really know your products?

Do they fully understand all indications and benefits?

What are the advantages over unbranded alternatives?

Why should they recommend your product?

At CIG Healthcare Partnership we understand that professional OTC training can transform a product’s sales success.

For nearly 40 years, we have been a leading provider of specialist multi-award winning training to major national and international healthcare retailers and manufacturers.

Whether it’s structured OTC learning programmes, pharmacist engagement tools or multi-language web-based e-learning hubs, we have the know-how, experience and talent to create and deliver behaviour changing knowledge Europe-wide.

GOOD OTC TRAINING KNOWS NO BOUNDARIES...

Bespoke Training Materials

Publications

Digital Communications

E-learning

Research

Events

www.cighealthcare.co.ukLinen Hall, 162-168 Regent Street, London W1B 5TB


7 avenue de Tervuren, B-1040 Brussels | Tel: +3227355130 | [email protected]

aesgp.eu

52nd AESGP Annual Meeting

Hotel Divani Apollon Palace

aesgp.eu/52

31 May 2016 - 2 June 2016 | Athens


aesgp programme

Documents